This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Okay, we are going to get started. I’m Liana Moussatos from Wedbush, and it’s our pleasure to have Joe Oliveto, CEO of Chelsea Therapeutics to give us a corporate update. Joe?
Joseph G. Oliveto
Thank you, Liana, and thanks to the Wedbush folks for inviting us today. Let’s see, great. First, just to remind you that we’ll be making the forward-looking statements I’ll direct you to the website where you can get our SEC filings, and we’ll get into the Northera droxidopa pitch. This slide, I’d like to remind people that well, the vast majority whatever we’ll be speaking about today is on our lead indication of neurogenic orthostatic hypotension and the company is very focused on neurogenic orthostatic hypotension. There’s a lot of legs behind droxidopa Northera for other indications, it’s on the market in Japan for Parkinson’s disease and intradialytic hypotension and (inaudible) studies at for fibromyalgia, ADHD and Parkinson’s Disease. So just want to leave you with the idea that there is a lot of opportunity for Northera once we get past the first hurdle for our lead indication.
Okay. So where is Northera? Northera is a prodrug of norepinephrine, it’s directly metabolized into norepinephrine, and it’s got a mechanism very similar or exactly similar to the way levodopa is converted, it’s a dopamine and that natural mechanism converting into norepinephrine the same endogenous of norepinephrine that you and I have in our bodies, so it lends itself to some safety advantages that you’ll see later on and it’s also the beneficiary of well documented safety and efficacy profile from being the market leader in Japan for the last couple of decades.